Education
About Us
Working with TipRanks
Follow Us
Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
LINCOLN Stock Chart & Stats
₹496.60
-₹14.55(-1.74%)
At close: 4:00 PM EST
₹496.60
-₹14.55(-1.74%)
Day’s Range― - ―
52-Week Range₹439.95 - ₹679.45
Previous CloseN/A
Volume57.32K
Average Volume (3M)1.66K
Market Cap
₹12.72B
Enterprise Value₹12.17B
Total Cash (Recent Filing)₹1.96B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)14.5
Beta1.52
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)14.28
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Near-zero Debt Balance SheetAn effectively debt-free balance sheet materially reduces solvency and interest-rate risk, leaving management optionality to fund capex, registrations, or M&A from internal resources. This financial flexibility supports durable investment and resilience across business cycles.
Strong Free Cash Flow ReboundA large rebound in free cash flow and improved coverage of net income indicate better cash conversion and operating efficiency. Sustained FCF enables organic growth, funds working capital, supports selective reinvestment or shareholder returns without relying on external financing.
Consistent Revenue Growth And Strong Gross MarginSteady top-line expansion combined with gross margins above 50% signals product mix strength and manufacturing/ pricing advantages. Durable revenue growth plus healthy gross margins underpin sustainable operating profitability and capacity to invest in portfolio expansion.
Bears Say
Margin CompressionDeclining EBITDA and net margins point to rising cost pressure or weaker pricing power. If structural, sustained margin compression will reduce free cash flow, limit reinvestment capacity, and erode return metrics, making growth less value-accretive over time.
Operating Cash Flow Below Net IncomePersistent shortfall of operating cash flow versus reported net income signals working-capital swings or timing gaps in cash realization. Continued variability can constrain liquidity for capex/dividends and may force reliance on short-term funding during growth phases.
ROE Stepped Down From Prior YearA material decline in ROE implies the company is generating lower returns on shareholder capital, possibly from margin pressure or faster equity growth. If sustained, this reduces capital efficiency and could limit long-term shareholder value creation.
Lincoln Pharmaceuticals Ltd News
LINCOLN FAQ
What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?
Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹679.45 in the past 12 months.
What is Lincoln Pharmaceuticals Ltd’s market cap?
Lincoln Pharmaceuticals Ltd’s market cap is ₹12.72B.
When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?
Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 86 days.
How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?
Lincoln Pharmaceuticals Ltd released its earnings results on Feb 12, 2026. The company reported ₹14.279 earnings per share for the quarter, beating the consensus estimate of N/A by ₹14.279.
Is Lincoln Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here
What is Lincoln Pharmaceuticals Ltd’s EPS estimate?
Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lincoln Pharmaceuticals Ltd have?
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.
What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?
Lincoln Pharmaceuticals Ltd reported an EPS of ₹14.279 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.516%.
Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:LINCOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
Technical Analysis
Kilitch Drugs (India) Limited
―
Kopran Limited
―
Themis Medicare Limited
―
Wanbury Limited
―
Anuh Pharma Limited
―